Beijing Balance Medical Technology Co., Ltd (SHA: 688198), a leading medical technology firm based in China, has achieved a significant regulatory milestone with the National Medical Products Administration’s (NMPA) approval for its heart valve biological patch. This marks the first market approval for a product specifically designed for the repair of heart valve leaflets and the shaping and reconstruction of aortic valve leaflets at various valve positions in the country. The product, derived from the leaflet sheet of Balance Medtech’s existing surgical bio valve, boasts identical chemical modification treatment, anti-calcification, and fatigue resistance characteristics, setting a new standard in the field of cardiovascular repair solutions.- Flcube.com
Recent news:
-
BRL Medicine Inc. Secures Nearly $30 Million in B+ Round Financing to Advance Pipeline -
Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies -
HutchMed Anticipates Milestone Payment as Takeda Launches Fruzaqla in Japan for CRC -
First Patient Dosed in Abbisko's Phase II Trial of ABSK061 and ABSK043 in FGFR2/3 Altered Tumors -
Bayer's Nubeqa Files for FDA Approval in mHSPC
